Arsenal Capital Partners is a private equity firm focused on middle-market healthcare, specialty industrial, and financial service companies. Specifically, Arsenal looks to acquire businesses in the areas of specialty chemicals, aerospace/defense, transportation, environmental services, business services, insurance, asset management, financial technology, medical products, healthcare IT, and healthcare contract research/manufacturing. The Firm typically seeks initial investment in companies with enterprise values between $100 to $250 million. Funds are generally used to support buyouts, recapitalizations, growth financings, consolidations, and divestitures. The Firm avoids investing in companies reliant on high levels of technology. Arsenal Capital Partners was formed in 2000 and is headquartered in New York City.
Join Mergr to view the latest updates and news from New York-based Arsenal Capital Partners.
In the last 3 years, Arsenal Capital Partners has acquired 6 companies. It has also invested in 3 others.
Arsenal Capital Partners’ most common sectors for investment are chemicals (34%) and business services (9%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (45%) and secondary buyout (25%). In total, Arsenal Capital Partners has invested in 19 US states and 2 different countries. Its largest (disclosed) acquisition occurred in 2017 when it acquired Spartech for $115M.
In the last 3 years, Arsenal Capital Partners has exited 8 companies. The Firm’s most common exit type is trade sale (50%). Arsenal Capital Partners’ largest (disclosed) exit occurred in 2017 when it sold Certara for $850M.
Join Mergr to view Arsenal Capital Partners’ full profile and discover more large private equity firms just like it.
No obligation. Cancel anytime.